UK: Clustered Regularly Interspaced Short Palindromic Repeats Gene Editing

Last Updated: 3 September 2018
Article by STA Law Firm

CRISPR Gene Editing Technology

The Human Advancement

Human often marvels at the things they create. From large structure to technologically mind-blowing machines, many impressive achievements warrant awe and amazement. A close look at these things will reveal their workings and both their strengths and their flaws. However, surrounded by all of this, one may forget from time to time to look, not only atones surroundings but also at one's self. Humans are vastly complex beings; perhaps more complicated than anything we will ever create. And yet for our entire history, we have concentrated on advancing the world around us while never genuinely having advanced ourselves.

One of the latest things we will hear about in the news and from the top scientific professionals is the matter of gene editing technology, most notably CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats). To be more specific to human use, CRISPR-Cas9, as before it was ever considered to use on humans, it was used to alter the genetics of other organisms. This scientific technique, which came into existence in around 2012, allows for the editing of the very genetic structure of an individual. The implications are massive, though the topic is quite decisive. Gene editing is something even scientist are still learning about, and the idea and practice are very much in its infancy.

One of the most significant areas of the whole practice is the idea and viability of using the CRISPR to edit the genes of embryos. Modifying the genes of embryos will allow for potential genetic mutations and genetic diseases to be removed from the child's genome before birth and could save a child from having to live with a potentially harmful or detrimental trait. The achievement can be by removing the specific set of coding in the embryos DNA that would be mutated and would cause the negative character, and to then use the CRISPR technology to implant the new genetic structure. It may sound all positive, though there are many implications and ethical dilemmas to consider.

The UK at the Forefront

The UK is making quite some progress in the matter of gene editing. They can see the potential benefits of the process when done correctly and are looking to move their knowledge of the topic forward. Around the start of 2016, UK scientists were given the go-ahead to begin testing and using CRISPR on human embryos for research purposes. It was approved of by the UK Human Fertilisation and Embryo Authority (HFEA) and was the first time something like this received approval outside China.

One thing to note is that this is not the first type of human genetic editing that has occurred. There have previously been gene therapies available, but not in the same way that CRISPR looks to move things forward. Prior, there was the possibility to have the genetics of somatic cells within an adult human edited for medical purposes. This form of editing was managed in the UK by the Human Tissue Authority (HTA), which received acknowledgment under the Human Tissue act of 2004. Now, this is a little divergent from the CRISPER concept, though it does show how the UK has been highly progressive in the matter of human genetic engineering. Having been established in 2004, this occurred around 11 years before the first human trials of CRISPER, and may very well have paved the way for the UK's future as a world leader in the area of early gene editing technology.

The hope is that the technology will, in time, be used for the curing of diseases and disabilities in embryos before they are born. The technology works by editing the DNA structure of the cells of an organism, by cutting away unwanted segments and adding in preferred portions. The research for the moment is concerned with fighting diseases that we have, up to this point, had no answer, and is mainly interested in the most negatively impacting diseases that there are. Since the science is not yet fully understood, it would more often than not, be seen as too high a risk to take for less problematic issues, though for the time, the research is being performed on spare IVF embryos usually only a few cells in size.

It is because gene editing is still looked upon skeptically by quite a few due to what it could lead to as it advances. There are ethical issues concerning the topic. The biggest of these seems to be the fear some have that there may come a time when designer babies become a thing. It will allow for certain individuals to pay to have their children's genetics altered to have favorable traits, including the appearance of the individual, and though we have an insufficient understanding of it at the moment, we may be able even genetically to modify individuals for higher intelligence and certain personality traits. It is very much a distant prospect, as we are still in the early stages of using the technology for simple and vital issues, though with the research into the issue growing, we will inevitably start to look into controversial areas such as these when they become a more comfortable thing to achieve. 

The Chinese have been attempting to use gene editing technology since around 2015, as far as we know, and have used the technique on approximately 86 or more people. Matters such as these in China are not as well known about regarding the details and results of tests. Further to this, the regulations regarding the issue are also different from much of the rest of the world, and so the Chinese may be more open to and freer regarding the matter and the research they perform. With this considered, it was in this year that a group of scientists did what no other individual or organization had done before. The concept had been extensively tested and was watertight. The biggest issue in testing for humans is that we are generally more complicated than the test analogs that we use. However, the Chinese researchers went ahead and performed the test as per their precise calculations on the previously mentioned 86 non-viable zygotes. In the end, the test was in many ways a failure though. Only 26 of the zygotes had their genomes successfully cleaved, and from a scientific standpoint, that is not a success rate. However, and more importantly, the research was underway

Outside of China though, the UK is at the forefront. The first law regarding the issue of genetic manipulation was the Genetic Manipulation Regulations of 1989. However, this law does not extend to humans. Preferably it is more concerned with the genetic manipulation of animals for the research purposes, which is something that has been allowed by the law for quite some time now, though it was not at that time see that it would be an issue for a human. The next big step in the UK was the limited go-ahead to certain scientific organizations to begin using and researching the practice in 2016

Regarding the human side of things, all matters to do with embryology are under the governance of the Human Fertilisation and Embryology Authority (HFEA). The HFEA has been given its powers through the Human Fertilisation and Embryos Act of 2008, though this was before the rise of CRISPR. As Crisper has come around, the HFEA has come up with their guidelines for researchers to abide. While the HFEA is most prominently known to cover the issues of fertility treatment etc. they now also deal with related matters including CRISPR.

Now while some scientists have been given the go-ahead by the HFEA to perform research using gene editing technologies, this by no stretch means that it is legal on a larger scale. The individuals allowed to conduct this research are insufficient in number, and since the HFEA is the only body in the UK that is permitted to provide the license required to do this research. Individuals should submit an application to them on the matter, and their issuing of the permit would be insufficient and strict, though not impossible. As recently as early as 2018, grants are issued in small numbers of new individuals and organizations.

The reason for the severe limitations to the number of groups that can use CRISPR to do research is because the issue is one that can be seen to be quite sensitive. There are many ethical dilemmas one must consider and not all will agree on the matters raised.

It is apparent that the HFEA has a policy that no gene editing research may take place without first obtaining research ethics approval, even by the approved bodies. What this means is that to perform analysis in genetic engineering for humans, one would first have to be approved of by the HFEA to be eligible to do this type of research, and then for every potential project of research they would look to perform, they would have to receive a further approval.

It ensures two things. Firstly, the research that scientists are doing is known to the regulatory bodies, and they are aware and up to date on what the licensed parties wish to do. Parties will get information about the research, and then the authorized bodies must wait until these proposals are accepted. Secondly, it allows people other than scientists to look into the issues that are for research and the methods that are being used to perform the investigation, and it provides for them to discuss them from an ethical standpoint. Once in-depth consideration is on the matter from multiple parties, it can then commence. As seen here, this is a highly regulated area, as it rightly should be, and it ensures we do not move forward into areas that can be dangerous.

Where is the Rest of the World?

While the UK is one of the countries at the forefront of gene editing research; other countries are also becoming more open to the prospect. While there are no laws that govern this field, too, there are generally no countries which allow for genetic engineering. It is often a banned practice except, as previously mentioned, for certain entities that have received the necessary approvals.

Considering the US, they were first given a yellow light (much like the UK, only the approved and licensed bodies may research into the field) to perform research in the area of human genetic engineering towards the beginning of 2017. They showed their first CRISPR genetic engineering to embryos towards the latter stages of 2017. With the case of the US, this allowance was only for research at first, with no editing to perform viable embryos that would go on to later be born, and substantial research would be required before this technology would become available to a further degree.

The issue was a scorching one during the year of 2016, with many on both sides of the table. Some were calling for a complete ban on the editing of human genetics in embryos, as they saw it leading to unethical practices and other who saw it as unnatural. In general within the country though, the method is still illegal, as none may perform practical research on the matter, and the only bodies that are allowed to, are highly official and highly regulated bodies. It would be near impossible for smaller organizations to obtain the license.

The US's governing body for the matters concerning the issue is the FDA (Food and Drug Administration). The FDA is in charge of promoting and protecting public health, and they enforce laws covered under this area. The department was empowered by the United States Congress to enforce the Federal Food, Drug, and Cosmetic Act, and that is their general purpose. Much like the HFEA, they have also allowed and approved of certain organizations performing research on embryos under 14 days old.

A case in the US that shows the earlier stages of the legal developments about genetics was the Association for Molecular Pathology v. Myriad Genetics. It was quite a lengthy case, beginning in 2010. Myriad Genetics Inc. was looking to patent genetic sequences. There was a considerable amount of back & forth in this case. Initially, two of Myriad's patents had been denied, though, upon appeal, the court reversed the decision. The legal battle between these parties continued, with arrangements being changed multiple times across a plethora of suits.  In the end, the case finally came to a close in 2013 with the conclusion that a genetic structure cannot receive a patent, as it is naturally occurring thing which does not meet the requirements for something to obtain a license. However, and this is where things become interesting, that manipulated genes, such as those created within a lab, were indeed eligible to be patented as they were not considered wholly natural and instead of a construct of human creativity. This entire issue occurred before CRISPR, though with the advancements that have occurred, the ruling is now more relevant than ever.

Looking to the Horizon

Regarding this issue, there may be those whose minds evoke images from horror movies, of genetic engineering going wrong. The scientist is performing illegal experiments and creating monsters that will be impossible to stop. However, in the real world, there are far too many guidelines, and far too many barriers to allow for any overly dramatic to occur. There is a reason the practice is still technically illegal, and only the bodies of the FDA and HFEA have, in their respective countries, empowered may progress. There is a reason that an ethics committee must approve of any of the planned activities. Also, this is to ensure a safe progression into the future, and a sequence which all can agree is acceptable and safe.

Looking beyond this and to the future though, the practice is one which has the potential to save the lives and improve quality of life for so many. As our understanding towards this topic increases, the legislators will pass more guidelines and laws to safeguard everyone's interest. There will be a more significant number of organizations and groups permitted to perform research in the fields. Also, as our knowledge expands, the areas we will be allowed to research will also grow. We are stepping forward on all the fronts, and the future awaits and looks brighter than ever

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions